Abstract 433P
Background
Robotic-assisted diagnosis and treatment in early gastric cancer represents an innovative approach leveraging advanced technology to enhance precision and efficacy in patient care. By integrating robotic systems into diagnostic procedures and minimally invasive surgeries, clinicians can achieve more accurate tumor localization, improved lymph node dissection, and precise tumor resection. This emerging field offers promising opportunities to optimize outcomes for patients with early-stage gastric cancer while minimizing surgical risks and preserving quality of life.
Methods
A comprehensive literature search was conducted across multiple databases from inception to December 25, 2023, following PRISMA guidelines. Randomized controlled trials (RCTs) comparing robotic-assissted endoscopic with conventional endoscopy in diagnosing and treating patients with gastric cancer were included. Data extraction, risk of bias assessment, and statistical analysis were performed using predefined methods.
Results
4 RCTs involving 8000 participants were included. Robotic-assisted endoscopy significantly reduced all-cause mortality (OR: 0.85, 95% CI: 0.76-0.96) and demonstrated a trend towards reducing complications (OR: 0.81, 95% CI: 0.61-1.08). Sensitivity analysis revealed a significant reduction in recurrence (OR: 0.56, 95% CI: 0.38-0.80) after excluding one study.
Conclusions
In conclusion, robotic-assisted diagnosis and treatment represent a paradigm shift in the management of early gastric cancer, offering precision, efficiency, and improved patient outcomes. The integration of robotic technology enhances diagnostic accuracy, facilitates minimally invasive procedures, and reduces postoperative complications. With its ability to navigate intricate anatomical structures and provide real-time imaging, robotic assistance empowers clinicians to deliver personalized and effective treatment strategies. As ongoing research continues to refine robotic platforms and techniques, the future holds great promise for further optimizing the diagnosis and management of early gastric cancer, ultimately benefiting patients worldwide.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.